Physiopathology of Prosthetic Joint Infections


This study aim to explore cellular responses of bone and immune cells to bacterial infections observed in patients with prosthetic joint infections. The investigators will analyze clinical data and tissue samples collected from patients undergoing surgery as part of their usual care for prosthetic joint infections. These research will be conducted on three different hospitals in Paris: Lariboisière (AP-HP), Cochin (AP-HP) and Croix Saint-Simon.

Full Title of Study: “Physiopathology of Prosthetic Joint Infections : a Pilot Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2022

Detailed Description

The number of prosthetic joint infections (PJI) new cases in France is estimated at 2000/2500 cases per year. PJI, mainly caused by staphylococci, are serious infections responsible for significant morbidity result of inflammation and bone destruction (osteomyelitis). Despite optimal medical and surgical management, a risk of failure and recurrence exists, which varies depending on the situation. In addition to the deterioration in patients' quality of life, the economic cost for the health care system is very high, in particular because of prolonged hospitalizations, complex treatments, and frequent readmissions. Thus, the adequate management of PJI is a major public health issue. In this context, new therapeutic approaches are urgent medical needs for the management of patients with PJI. Thus, the identification of the biological mechanisms (immunology, microbiology, bone physiology) underlying these infections is essential. Indeed, the impact of bacterial infections on bone homeostasis is poorly documented. Although several biological mechanisms have been suggested the host-pathogen interaction and the close links between bacterial infection and biological response of bone cells to microorganisms and their environment warrant to be explored.

Arms, Groups and Cohorts

  • septic samples
    • patients undergoing revision surgery for prosthetic joint infection
  • aseptic samples
    • patients undergoing revision surgery for prosthetic replacement without infection

Clinical Trial Outcome Measures

Primary Measures

  • markers of bone loss
    • Time Frame: 12 months
    • Immunohistochemistry detection of Tartrate-resistant acid phosphatase cells (TRAP); cathepsin K; Matrix Metalloproteinase 9 (MMP9); sclerostin

Secondary Measures

  • markers of cellular activity in the bone microenvironment
    • Time Frame: 12 months
    • immunohistochemistry detection of nuclear factor-activated T cells c1 (NFATc1); Matrix Metalloproteinase 9 (MMP9); Fibroblast growth factor 23 (FGF23)
  • immune-profiling of bone microenvironment
    • Time Frame: 12 months
    • mapping lymphoid and myeloid cells by spectral flow cytometry assay
  • inflammatory mediators in the bone microenvironment
    • Time Frame: 12 months
    • flow cytometry quantification of cytokine producing cells
  • differentiation between osteoclasts from mononuclear phagocytes
    • Time Frame: 12 months
    • enzyme-linked immunosorbent (ELISA) and/or flow cytometry assays using specific antibodies

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years-old and older – Patient eligible for lower limb revision surgery (revision surgery for infected or non-infected prosthesis) – Patient affiliated to a social security system – Oral consent to the research Exclusion Criteria:

  • NA

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Martine COHEN-SOLAL, MD, PhD, Principal Investigator, Assistance Publique – Hôpitaux de Paris
  • Overall Contact(s)
    • Martine COHEN-SOLAL, MD, PhD, +33(0)1 49 95 63 58,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.